https://mindmedicinelaw.com/briefing/cost-effectiveness-of-ketamine-vs-ect-in-us-depression-care-20261022-52806The Psychedelic Journalen2026-10-22T22:05:06.409472+00:00Cost-Effectiveness of Ketamine vs. ECT in US Depression Careketamine, electroconvulsive therapy, treatment-resistant depression, cost-effectiveness, quality-adjusted life-years, clinical guidelines, health policy, insurance reimbursement, psychiatric treatments, depression carehttps://mindmedicinelaw.com/briefing/cbp-delays-de-minimis-exemption-suspension-implications-for-psychedelic-imports-20261022-52553The Psychedelic Journalen2026-10-22T15:05:42.120726+00:00CBP Delays De Minimis Exemption Suspension: Implications for Psychedelic Importscbp de minimis exemption, psychedelic research imports, mail shipment regulation, customs compliance, research chemicals, us customs and border protection, policy change, supply chain risk, federal register, drug import controlshttps://mindmedicinelaw.com/briefing/low-dose-ketamine-for-depression-clinical-evidence-and-policy-in-2026-20261021-52631The Psychedelic Journalen2026-10-22T15:05:14.694482+00:00Low-Dose Ketamine for Depression: Clinical Evidence and Policy in 2026ketamine, treatment-resistant depression, bipolar depression, meta-analysis, clinical guidelines, long-term safety, FDA, psychiatry, rapid-acting antidepressants, policy implicationshttps://mindmedicinelaw.com/briefing/expectation-bias-in-psychedelic-trials-implications-for-research-validity-20261021-52617The Psychedelic Journalen2026-10-22T15:04:58.859041+00:00Expectation Bias in Psychedelic Trials: Implications for Research Validitypsychedelic clinical trials, expectation bias, participant selection, trial generalizability, regulatory implications, chronic pain research, personality traits, clinical trial design, selection bias, psychedelic researchhttps://mindmedicinelaw.com/briefing/psilocybin-reduces-inflammation-in-parkinson-s-u-s-phase-2-data-20261021-52523The Psychedelic Journalen2026-10-21T22:03:47.873289+00:00Psilocybin Reduces Inflammation in Parkinson’s: U.S. Phase 2 Datapsilocybin, parkinson's disease, clinical trial, inflammation, neuroprotection, phase 2, biomarkers, psychedelic research, regulatory policyhttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-wellbeing-gains-in-social-anxiety-trials-20261020-52779The Psychedelic Journalen2026-10-22T22:05:18.856215+00:00MDMA-Assisted Therapy: Wellbeing Gains in Social Anxiety Trialsmdma-assisted therapy, social anxiety disorder, self-transcendent emotions, psychological flourishing, clinical trial outcomes, wellbeing measures, psychedelic research, regulatory implications, mechanisms of actionhttps://mindmedicinelaw.com/briefing/omics-informed-tms-mechanisms-in-trd-implications-for-psychedelic-research-20261020-52618The Psychedelic Journalen2026-10-22T15:05:58.125417+00:00Omics-Informed TMS Mechanisms in TRD: Implications for Psychedelic Researchtranscranial magnetic stimulation, treatment-resistant depression, omics, biomarkers, neuroplasticity, psychedelic research, clinical trial design, mechanisms of action, regulatory policyhttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-and-flourishing-new-insights-from-u-s-social-anxiety-trial-20261020-52263The Psychedelic Journalen2026-10-21T15:06:52.992608+00:00MDMA-Assisted Therapy and Flourishing: New Insights from U.S. Social Anxiety Trialsmdma-assisted therapy, social anxiety disorder, self-transcendent experiences, psychological flourishing, clinical trial outcomes, wellbeing measures, regulatory implications, psychedelic research, fda guidance, trial designhttps://mindmedicinelaw.com/briefing/deep-learning-boosts-preclinical-sleep-analysis-in-psychedelic-studies-20261020-52243The Psychedelic Journalen2026-10-21T15:06:35.019841+00:00Deep Learning Boosts Preclinical Sleep Analysis in Psychedelic Studiesdeep learning, sleep stage classification, preclinical research, psychedelic drugs, EEG analysis, pharmacological interventions, neuroscience, automated annotation, translational researchhttps://mindmedicinelaw.com/briefing/social-responsibility-in-psychedelic-research-integrating-ethnic-minorities-20261019-52621The Psychedelic Journalen2026-10-22T15:06:11.926716+00:00Social Responsibility in Psychedelic Research: Integrating Ethnic Minoritiespsychedelic research, ethnic minority integration, indigenous communities, afro-descendant inclusion, social responsibility, decolonizing methodologies, health policy, extractive industries, intercultural justice, benefit sharinghttps://mindmedicinelaw.com/briefing/mazatec-mushroom-medicine-ethics-and-the-western-psychedelic-renaissance-20261019-52278The Psychedelic Journalen2026-10-21T15:09:14.311272+00:00Mazatec Mushroom Medicine, Ethics, and the Western Psychedelic Renaissancemazatec mushroom medicine, psilocybin commercialization, michael pollan, indigenous rights, benefit-sharing, psychedelic industry ethics, cultural appropriation, settler colonialism, policy frameworks, reciprocityhttps://mindmedicinelaw.com/briefing/brain-connectivity-in-anhedonia-implications-for-psychedelic-trials-20261019-52245The Psychedelic Journalen2026-10-21T15:08:33.024502+00:00Brain Connectivity in Anhedonia: Implications for Psychedelic Trialsanhedonia, cortico-subcortical connectivity, psychedelic clinical trials, biomarkers, neural hierarchy, fMRI, mood disorders, mechanistic targets, transdiagnostic research, regulatory sciencehttps://mindmedicinelaw.com/briefing/lhb-remodeling-and-antidepressant-timing-ketamine-insights-for-depression-20261019-52276The Psychedelic Journalen2026-10-21T15:08:03.067260+00:00LHb Remodeling and Antidepressant Timing: Ketamine Insights for Depressionlateral habenula, ketamine, depression, spatial transcriptomics, chronic stress, rapid-acting antidepressants, clinical trial design, neurobiology of depression, psychedelic researchhttps://mindmedicinelaw.com/briefing/hhc-associated-psychosis-distinct-clinical-features-in-irish-inpatient-cohort-20261019-52246The Psychedelic Journalen2026-10-21T15:07:18.357245+00:00HHC-Associated Psychosis: Distinct Clinical Features in Irish Inpatient Cohorthhc psychosis, novel cannabinoids, cannabis-associated psychosis, psychiatric screening, toxicology, ireland mental health, public health policy, affective symptoms, thought disorder, first episode psychosishttps://mindmedicinelaw.com/briefing/ketamine-assisted-psychotherapy-alters-dna-methylation-in-mdd-patients-20261015-52691The Psychedelic Journalen2026-10-22T15:05:27.212174+00:00Ketamine-Assisted Psychotherapy Alters DNA Methylation in MDD Patientsketamine-assisted psychotherapy, dna methylation, major depressive disorder, epigenetics, psychedelic research, biomarker development, clinical trial design, regulatory policy, psychiatric intervention, longitudinal study